Search Results

Factors Associated with Serious Adverse Reactions to Cholinesterase Inhibitors: A Study of Spontaneous Reporting

Authors: Pariente, Antoine; Sanctussy, Dina Joseph-Reinette; Miremont-Salamé, Ghada; Moore, Nicholas; Haramburu, Françoise; Fourrier-Réglat, Annie

Source: CNS Drugs, Volume 24, Number 1, 1 January 2010 , pp. 55-63(9)

Publisher: Adis International

Donepezil cost saving to society in moderate-to-severe AD

Source: PharmacoEconomics and Outcomes News, Volume 1, Number 463, 2004-10-09 , pp. 7-7(1)

Publisher: Adis International

Donepezil cost saving to society in moderate-to-severe AD

Source: Inpharma, Volume 1, Number 1460, 2004-10-23 , pp. 6-6(1)

Publisher: Adis International

News from the European Federation of Neurological Societies Congress

Source: Inpharma, Volume 1, Number 1460, 2004-10-23 , pp. 14-15(2)

Publisher: Adis International

Galantamine worth it for AD in many countries

Source: Inpharma, Volume 1, Number 1455, 2004-09-18 , pp. 4-4(1)

Publisher: Adis International

R&D news from the 9th International Conference on Alzheimer's Disease

Source: Inpharma, Volume 1, Number 1455, 2004-09-18 , pp. 6-7(2)

Publisher: Adis International

News from the 9th International Conference on Alzheimer's Disease

Source: Inpharma, Volume 1, Number 1456, 2004-09-25 , pp. 14-15(2)

Publisher: Adis International

Galantamine worth it for AD in many countries

Source: PharmacoEconomics and Outcomes News, Volume 1, Number 462, 2004-09-25 , pp. 5-5(1)

Publisher: Adis International

Memantine cost saving in moderately-severe to severe AD

Source: Inpharma, Volume 1, Number 1450, 2004-08-14 , pp. 5-5(1)

Publisher: Adis International

Pharmacoeconomics news from the 9th International Conference on Alzheimer's Disease and Related Disorders

Source: Inpharma, Volume 1, Number 1447, 2004-07-24 , pp. 5-6(2)

Publisher: Adis International

Donepezil study underpowered, say Eisai and Pfizer

Source: Inpharma, Volume 1, Number 1446, 2004-07-17 , pp. 2-2(1)

Publisher: Adis International

Memantine cost saving for AD in Finland

Source: Inpharma, Volume 1, Number 1446, 2004-07-17 , pp. 4-4(1)

Publisher: Adis International

Donepezil study underpowered, say Eisai and Pfizer

Source: PharmacoEconomics and Outcomes News, Volume 1, Number 457, 2004-07-17 , pp. 2-2(1)

Publisher: Adis International

Memantine cost saving for AD in Finland

Source: PharmacoEconomics and Outcomes News, Volume 1, Number 457, 2004-07-17 , pp. 7-7(1)

Publisher: Adis International

Under a bill honouring former US President Ronald Reagan, US NIH funding for Alzheimer's disease (AD) research would reach $US1.4 billion

Source: PharmacoEconomics and Outcomes News, Volume 1, Number 455, 2004-06-19 , pp. 11-11(1)

Publisher: Adis International

Value of donepezil doubtful in Alzheimer's disease

Source: Inpharma, Volume 1, Number 1444, 2004-07-03 , pp. 7-7(1)

Publisher: Adis International

Value of donepezil doubtful in Alzheimer's disease

Source: PharmacoEconomics and Outcomes News, Volume 1, Number 456, 2004-07-03 , pp. 9-9(1)

Publisher: Adis International

The US Alzheimer's Association is calling on Congress to increase federal investment in Alzheimer's research at the NIH to at least $US1 billion annually.

Source: PharmacoEconomics and Outcomes News, Volume 1, Number 456, 2004-07-03 , pp. 11-11(1)

Publisher: Adis International

Donepezil enhances cognitive function, QOL in AD

Source: PharmacoEconomics and Outcomes News, Volume 1, Number 453, 2004-05-22 , pp. 3-4(2)

Publisher: Adis International

Doxycycline + rifampicin worth a try in AD?

Source: Inpharma, Volume 1, Number 1436, 2004-05-08 , pp. 13-13(1)

Publisher: Adis International